BACKGROUND: Both radioactive iodine (RAI) and external beam radiation therapy (EBRT) offer important clinical benefits in properly selected patients with differentiated thyroid cancer. With the increased emphasis on a risk-adapted model for the management of thyroid cancer, it is important to identify which patients are most likely to benefit from radiation therapies given in the adjuvant setting and as treatment of gross residual disease. METHODS: This review compares the authors' current management practices with the recommendations of published guidelines from both the National Comprehensive Cancer Network and the American Thyroid Association. RESULTS: Because of the lack of prospective randomized studies on either RAI or EBRT in differentiated thyroid cancer, recommendations must be based on retrospective cohort studies that vary in selection criteria, histologies, sample size, inclusion criteria, and follow-up. CONCLUSIONS: RAI has an important adjuvant therapy and treatment function in properly selected patients. Likewise, EBRT is associated with increased locoregional control and palliative therapeutic effects in high-risk patients.
BACKGROUND: Both radioactive iodine (RAI) and external beam radiation therapy (EBRT) offer important clinical benefits in properly selected patients with differentiated thyroid cancer. With the increased emphasis on a risk-adapted model for the management of thyroid cancer, it is important to identify which patients are most likely to benefit from radiation therapies given in the adjuvant setting and as treatment of gross residual disease. METHODS: This review compares the authors' current management practices with the recommendations of published guidelines from both the National Comprehensive Cancer Network and the American Thyroid Association. RESULTS: Because of the lack of prospective randomized studies on either RAI or EBRT in differentiated thyroid cancer, recommendations must be based on retrospective cohort studies that vary in selection criteria, histologies, sample size, inclusion criteria, and follow-up. CONCLUSIONS:RAI has an important adjuvant therapy and treatment function in properly selected patients. Likewise, EBRT is associated with increased locoregional control and palliative therapeutic effects in high-risk patients.
Authors: Elisabeth Mamelle; Isabelle Borget; Sophie Leboulleux; Haïtham Mirghani; Carlos Suárez; Phillip K Pellitteri; Ashok R Shaha; Marc Hamoir; K Thomas Robbins; Avi Khafif; Juan P Rodrigo; Carl E Silver; Alessandra Rinaldo; Alfio Ferlito; Dana M Hartl Journal: Eur Arch Otorhinolaryngol Date: 2014-06-11 Impact factor: 2.503
Authors: Samantha Tam; Moran Amit; Mongkol Boonsripitayanon; Maria E Cabanillas; Naifa L Busaidy; G Brandon Gunn; Stephen Y Lai; Neil D Gross; Erich M Sturgis; Mark E Zafereo Journal: JAMA Otolaryngol Head Neck Surg Date: 2017-12-01 Impact factor: 6.223
Authors: Ana P Kiess; Nishant Agrawal; James D Brierley; Umamaheswar Duvvuri; Robert L Ferris; Eric Genden; Richard J Wong; R Michael Tuttle; Nancy Y Lee; Gregory W Randolph Journal: Head Neck Date: 2015-12-30 Impact factor: 3.147
Authors: Hyoung Shin Lee; Sung Won Kim; Taejung Park; Gi Yun Nam; Jong Chul Hong; Kang Dae Lee Journal: World J Surg Date: 2015-04 Impact factor: 3.352
Authors: Dana M Hartl; Elisabeth Mamelle; Isabelle Borget; Sophie Leboulleux; Haïtham Mirghani; Martin Schlumberger Journal: World J Surg Date: 2013-08 Impact factor: 3.352
Authors: Megan R Haymart; Mousumi Banerjee; Di Yang; Andrew K Stewart; Jennifer J Griggs; James C Sisson; Ronald J Koenig Journal: Endocr Pract Date: 2013 Jul-Aug Impact factor: 3.443